# R-Pharm clinical trials: 58 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 58 trials with R-Pharm as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by R-Pharm: 58 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/r-pharm

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 19, 2026 | NCT07880886 | Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or... | R-Pharm | Phase 3 | Not yet recruiting | Familial Mediterranean Fever, FMF | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880886) |
| May 19, 2026 | NCT07597668 | A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With... | R-Pharm | Phase 1 | Active not recruiting | Multiple Sclerosis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597668) |
| April 22, 2026 | NCT07543744 | A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer... | R-Pharm | Phase 1 | Recruiting | Metastatic Colorectal Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543744) |
| February 27, 2026 | NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell... | R-Pharm | Phase 3 | Completed | Head and Neck Squamous Cell Carcinoma | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435324) |
| February 27, 2026 | NCT07435311 | A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head... | R-Pharm | Phase 1 | Completed | Head and Neck Squamous Cell Carcinoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435311) |
| February 4, 2026 | NCT07386938 | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line... | R-Pharm | Phase 3 | Active not recruiting | Locally Advanced Breast Cancer, Metastatic Breast Cancer | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07386938) |
| March 20, 2024 | NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | R-Pharm | Phase 3 | Completed | Skin Melanoma | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06320353) |
| March 12, 2024 | NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | R-Pharm | Phase 1 | Completed | Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06307093) |
| March 17, 2023 | NCT05773170 | Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent... | R-Pharm | Observational | Completed | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Atrial Flutter | 1,147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05773170) |
| January 19, 2022 | NCT05196477 | Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection | R-Pharm | Observational | Completed | COVID-19 | 3,087 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05196477) |
| January 12, 2022 | NCT05187793 | Study of Efficacy of Different Treatment Regimens of Olokizumab | R-Pharm | Phase 3 | Unknown | COVID-19 | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05187793) |
| February 18, 2021 | NCT04760730 | Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of... | R-Pharm | Phase 1/2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04760730) |
| December 29, 2020 | NCT04686773 | Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19... | R-Pharm | Phase 2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04686773) |
| December 24, 2020 | NCT04684446 | Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 | R-Pharm | Phase 1/2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04684446) |
| August 6, 2020 | NCT04501783 | Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 | R-Pharm | Phase 3 | Completed | COVID-19 | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04501783) |
| June 30, 2020 | NCT04452474 | Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With... | R-Pharm | Phase 2/3 | Withdrawn | COVID-19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04452474) |
| January 29, 2020 | NCT04246723 | Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C... | R-Pharm | Phase 2 | Completed | Chronic Hepatitis c Genotype 1 | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04246723) |
| August 26, 2019 | NCT04067492 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute... | R-Pharm | Phase 2 | Terminated | Gout Attack | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04067492) |
| February 7, 2019 | NCT03833362 | Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated... | R-Pharm | Phase 3 | Completed | Hepatitis C | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03833362) |
| February 6, 2019 | NCT03832426 | A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy... | R-Pharm | Phase 1 | Completed | Hepatic Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03832426) |
| September 13, 2018 | NCT03669484 | Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General... | R-Pharm | Phase 3 | Completed | General Anaesthesia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03669484) |
| September 10, 2018 | NCT03663374 | Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence | R-Pharm | Phase 3 | Completed | Alcohol Dependence | 644 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03663374) |
| September 6, 2018 | NCT03659305 | Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin® | R-Pharm | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03659305) |
| July 2, 2018 | NCT03575702 | Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. | R-Pharm | Phase 3 | Completed | Overactive Bladder | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03575702) |
| June 11, 2018 | NCT03551210 | Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia | R-Pharm | Phase 3 | Completed | Pneumonia, Bacterial | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03551210) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 3 |
| Phase 2 | 16 |
| Phase 2/3 | 1 |
| Phase 3 | 15 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 46 |
| Terminated | 5 |
| Active not recruiting | 2 |
| Unknown | 2 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 15 |
| Neoplasms | 8 |
| COVID-19 | 7 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Respiration Disorders | 4 |
| Lung Diseases | 4 |
| Coronavirus Infections | 4 |
| Hepatitis C | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Neoplasm Metastasis | 2 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Melanoma | 2 |
| Lung Neoplasms | 2 |
| Multiple Sclerosis | 1 |
| Coinfection | 1 |
| Alcoholism | 1 |
| Familial Mediterranean Fever | 1 |
| Carcinoma | 1 |
| Atrial Fibrillation | 1 |
| Atrial Flutter | 1 |
| Pancreatic Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Hepatitis | 1 |
| Stomach Neoplasms | 1 |
| Pneumonia, Bacterial | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Inspection companies in the United States](https://specstream.ai/data/businesses/inspection-companies/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
